董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aetna Wun Trombley | 女 | Director,Chief Executive Officer and President | 47 | 72.85万美元 | 205.09 | 2026-09-30 |
| Clare Ozawa | 女 | Independent Director | 52 | 未披露 | 20.52 | 2026-09-30 |
| Tim Anderson | 男 | Independent Director | 36 | 未披露 | 未持股 | 2026-09-30 |
| Jane Pritchett Henderson | 女 | Independent Director | 60 | 未披露 | 5.77 | 2026-09-30 |
| Ming Fang | 男 | Independent Director | 45 | 未披露 | 未持股 | 2026-09-30 |
| William J. Rieflin | 男 | Chair of the Board and Independent Director | 66 | 未披露 | 14.90 | 2026-09-30 |
| Laurent Fischer | 男 | Independent Director | 62 | 未披露 | 5.99 | 2026-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aetna Wun Trombley | 女 | Director,Chief Executive Officer and President | 47 | 72.85万美元 | 205.09 | 2026-09-30 |
| Chin Lee | 男 | Chief Medical Officer | 57 | 125.50万美元 | 43.96 | 2026-09-30 |
| Chin Lee | -- | Chief Medical Officer | 57 | 未披露 | 未持股 | 2026-09-30 |
| Sofia Touami | 女 | Chief Business Officer | 56 | 未披露 | 未持股 | 2026-09-30 |
| Amy Bachrodt | 女 | Chief Financial Officer | 47 | 未披露 | 未持股 | 2026-09-30 |
| Steve Staben | 男 | Chief Scientific Officer | 46 | 56.66万美元 | 51.01 | 2026-09-30 |
董事简历
中英对照 | 中文 | 英文- Aetna Wun Trombley
-
Aetna Wun Trombley自2020年4月起担任首席执行官兼总裁、董事会成员。Trombley博士自2023年10月起担任风险生物技术公司TCG Labs Soleil的战略董事会成员，此前曾于2016年5月至2024年1月担任临床阶段生物技术公司Carmot Therapeutics Inc.（被F. Hoffmann La Roche Ltd收购）的董事会成员。从2011年9月到2020年3月，Trombley博士在生物技术公司NGM生物制药公司担任越来越重要的职务，最近担任总裁兼首席运营官。Trombley博士此前曾在诺华公司和麦肯锡公司任职。Trombley博士获得了加州大学圣地亚哥分校的化学学士学位和麻省理工学院的化学博士学位。
Aetna Wun Trombley has served as Chief Executive Officer and President and a member of board of directors since April 2020. Dr. Trombley has served as a member of the strategic board of TCG Labs Soleil, a venture biotechnology company, since October 2023 and previously served as a member of the board of directors of Carmot Therapeutics Inc. (acquired by F. Hoffmann La Roche Ltd), a clinical stage biotechnology company, from May 2016 to January 2024. From September 2011 to March 2020, Dr. Trombley held roles of increasing responsibility at NGM Biopharmaceuticals, Inc., a biotechnology company, most recently as President and Chief Operating Officer. Dr. Trombley previously held positions with Novartis AG and McKinsey & Company. Dr. Trombley received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from the Massachusetts Institute of Technology. - Aetna Wun Trombley自2020年4月起担任首席执行官兼总裁、董事会成员。Trombley博士自2023年10月起担任风险生物技术公司TCG Labs Soleil的战略董事会成员，此前曾于2016年5月至2024年1月担任临床阶段生物技术公司Carmot Therapeutics Inc.（被F. Hoffmann La Roche Ltd收购）的董事会成员。从2011年9月到2020年3月，Trombley博士在生物技术公司NGM生物制药公司担任越来越重要的职务，最近担任总裁兼首席运营官。Trombley博士此前曾在诺华公司和麦肯锡公司任职。Trombley博士获得了加州大学圣地亚哥分校的化学学士学位和麻省理工学院的化学博士学位。
- Aetna Wun Trombley has served as Chief Executive Officer and President and a member of board of directors since April 2020. Dr. Trombley has served as a member of the strategic board of TCG Labs Soleil, a venture biotechnology company, since October 2023 and previously served as a member of the board of directors of Carmot Therapeutics Inc. (acquired by F. Hoffmann La Roche Ltd), a clinical stage biotechnology company, from May 2016 to January 2024. From September 2011 to March 2020, Dr. Trombley held roles of increasing responsibility at NGM Biopharmaceuticals, Inc., a biotechnology company, most recently as President and Chief Operating Officer. Dr. Trombley previously held positions with Novartis AG and McKinsey & Company. Dr. Trombley received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
- Clare Ozawa
-
Clare Ozawa自2019年2月以来一直担任我们的董事会成员。Ozawa博士自2017年7月起担任Versant Venture Management LLC Versant（一家生命科学风险投资公司，投资于早期梦百合公司）的董事总经理，并于2008年至2011年担任Versant的投资专业人士。在重新加入Versant之前，小泽博士于2011年1月至2014年5月担任Inception Sciences（Inception）的首席商务官，并于2014年6月至2017年7月担任Inception’；的首席运营官。她也曾任职Novartis公司（从2006年到2008年）、McKinsey&Company（从2002年到2006年）的首席执行官办公室。Ozawa博士在斯坦福大学（Stanford University）获得生物科学学士学位和神经科学博士学位。
Clare Ozawa has served as a member of our board of directors since February 2019. Dr. Ozawa has served as a Managing Director at Versant Venture Management LLC Versant, a life science venture capital firm investing in early stage healthcare companies, since July 2017 and was an investment professional at Versant from 2008 to 2011. Prior to re-joining Versant, Dr. Ozawa was the Chief Business Officer of Inception Sciences (Inception) from January 2011 to May 2014 and served as Inception’s Chief Operating Officer from June 2014 to July 2017. She also worked in the Office of the Chief Executive Officer at Novartis from 2006 to 2008 and at McKinsey & Company from 2002 to 2006. Dr. Ozawa received a B.S. in biological sciences and a Ph.D. in neurosciences from Stanford University. - Clare Ozawa自2019年2月以来一直担任我们的董事会成员。Ozawa博士自2017年7月起担任Versant Venture Management LLC Versant（一家生命科学风险投资公司，投资于早期梦百合公司）的董事总经理，并于2008年至2011年担任Versant的投资专业人士。在重新加入Versant之前，小泽博士于2011年1月至2014年5月担任Inception Sciences（Inception）的首席商务官，并于2014年6月至2017年7月担任Inception’；的首席运营官。她也曾任职Novartis公司（从2006年到2008年）、McKinsey&Company（从2002年到2006年）的首席执行官办公室。Ozawa博士在斯坦福大学（Stanford University）获得生物科学学士学位和神经科学博士学位。
- Clare Ozawa has served as a member of our board of directors since February 2019. Dr. Ozawa has served as a Managing Director at Versant Venture Management LLC Versant, a life science venture capital firm investing in early stage healthcare companies, since July 2017 and was an investment professional at Versant from 2008 to 2011. Prior to re-joining Versant, Dr. Ozawa was the Chief Business Officer of Inception Sciences (Inception) from January 2011 to May 2014 and served as Inception’s Chief Operating Officer from June 2014 to July 2017. She also worked in the Office of the Chief Executive Officer at Novartis from 2006 to 2008 and at McKinsey & Company from 2002 to 2006. Dr. Ozawa received a B.S. in biological sciences and a Ph.D. in neurosciences from Stanford University.
- Tim Anderson
-
Tim Anderson自2021年9月起担任董事会成员。安德森先生自2023年12月起担任Blue Owl Capital Inc.的董事总经理，并担任其医疗保健机会投资团队的成员。安德森先生此前曾于2014年7月至2023年11月在生命科学投资管理公司高宏集团 Healthcare Investments担任董事总经理，并于2011年7月至2014年10月在高宏集团公司担任投资银行业务助理。安德森先生目前担任临床阶段药物开发公司Windward Bio AG的董事，自2025年1月起，生物技术公司Nuvig Therapeutics，Inc.自2024年12月起，生物技术公司F2G Ltd自2020年8月起，生物技术公司Autobahn Therapeutics，Inc.自2020年5月起。安德森先生在鲍登学院获得了经济学和政府与法律研究学士学位。
Tim Anderson has served as a member of board of directors since September 2021. Mr. Anderson has served as a Managing Director at Blue Owl Capital Inc. and as a member of its Healthcare Opportunities Investment Team since December 2023. Mr. Anderson previously served as a Managing Director at Cowen Healthcare Investments, a life sciences investment manager, from July 2014 to November 2023, and as an Investment Banking Associate at Cowen and Company from July 2011 to October 2014. Mr. Anderson currently serves as a director of Windward Bio AG, a clinical stage drug development company, since January 2025, Nuvig Therapeutics, Inc., a biotechnology company, since December 2024, F2G Ltd, a biotechnology company, since August 2020 and Autobahn Therapeutics, Inc., a biotechnology company, since May 2020. Mr. Anderson received a B.A. in Economics and Government & Legal Studies from Bowdoin College. - Tim Anderson自2021年9月起担任董事会成员。安德森先生自2023年12月起担任Blue Owl Capital Inc.的董事总经理，并担任其医疗保健机会投资团队的成员。安德森先生此前曾于2014年7月至2023年11月在生命科学投资管理公司高宏集团 Healthcare Investments担任董事总经理，并于2011年7月至2014年10月在高宏集团公司担任投资银行业务助理。安德森先生目前担任临床阶段药物开发公司Windward Bio AG的董事，自2025年1月起，生物技术公司Nuvig Therapeutics，Inc.自2024年12月起，生物技术公司F2G Ltd自2020年8月起，生物技术公司Autobahn Therapeutics，Inc.自2020年5月起。安德森先生在鲍登学院获得了经济学和政府与法律研究学士学位。
- Tim Anderson has served as a member of board of directors since September 2021. Mr. Anderson has served as a Managing Director at Blue Owl Capital Inc. and as a member of its Healthcare Opportunities Investment Team since December 2023. Mr. Anderson previously served as a Managing Director at Cowen Healthcare Investments, a life sciences investment manager, from July 2014 to November 2023, and as an Investment Banking Associate at Cowen and Company from July 2011 to October 2014. Mr. Anderson currently serves as a director of Windward Bio AG, a clinical stage drug development company, since January 2025, Nuvig Therapeutics, Inc., a biotechnology company, since December 2024, F2G Ltd, a biotechnology company, since August 2020 and Autobahn Therapeutics, Inc., a biotechnology company, since May 2020. Mr. Anderson received a B.A. in Economics and Government & Legal Studies from Bowdoin College.
- Jane Pritchett Henderson
-
Jane Pritchett Henderson，自2023年1月起担任Apogee Therapeutics公司首席财务官。在加入Apogee之前，Henderson女士于2020年12月至2022年11月担任Adagio Therapeutics, Inc.（现为Invivyd，Inc.）（纳斯达克：IVVD）的首席财务官和首席商务官。Adagio Therapeutics，Inc.是一家为冠状病毒开发抗体疗法的生物技术公司。在加入Adagio Therapeutics之前，亨德森女士于2018年6月至2020年12月担任私营病毒免疫肿瘤公司Turnstone Biologics Corp.的首席财务官,2017年1月至2018年6月担任基因治疗公司Voyager Therapeutics, Inc.（纳斯达克：VYGR）的首席财务官和企业发展高级副总裁，并于2013年2月至2016年11月担任私营肿瘤生物制药公司Kolltan制药公司的高级副总裁、首席财务和业务官，Kolltan制药被Kolltan制药收购之前，在医疗保健投资银行工作了近20年后，亨德森在生物制药公司担任过各种财务和业务发展主管职务。在过去五年中，亨德森女士自2019年4月起担任生物技术公司Akero Therapeutics, Inc.（纳斯达克：AKRO）的董事会成员，自2018年1月起担任生物制药公司IVERIC Bio，Inc.（纳斯达克：ISEE）的董事会成员，以及私营生物制药公司Ventus Therapeutics，Inc.的董事会成员。2018年10月至2021年11月，她还担任生物制药公司Sesen Bio公司（纳斯达克：SESN）的董事会成员。亨德森女士还在南方卫理公会大学戴德曼学院执行委员会任职。亨德森在杜克大学获得了心理学学士学位。
Jane Pritchett Henderson,has served as Apogee Therapeutics, Inc. Chief Financial Officer since January 2023. Prior to joining Apogee, Ms. Henderson served as the Chief Financial Officer and Chief Business Officer of Adagio Therapeutics, Inc. (now Invivyd, Inc.) (Nasdaq: IVVD), a biotechnology company developing antibody therapeutics for coronaviruses, from December 2020 to November 2022. Prior to joining Adagio Therapeutics, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics Corp., a private viral immuno-oncology company, from June 2018 to December 2020, as Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company, from January 2017 to June 2018, and as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., a private oncology biopharmaceutical company, from February 2013 until November 2016, when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in health care investment banking. During the past five years, Ms. Henderson has served on the board of directors of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since April 2019, IVERIC Bio, Inc. (Nasdaq: ISEE), a biopharmaceutical company, since January 2018, and Ventus Therapeutics, Inc., a private biopharmaceutical company. She also served on the board of directors of Sesen Bio Inc. (Nasdaq: SESN), a biopharmaceutical company, from October 2018 to November 2021. Ms. Henderson also serves on the Dedman College Executive Board of Southern Methodist University. Ms. Henderson received a B.S. in psychology from Duke University. - Jane Pritchett Henderson，自2023年1月起担任Apogee Therapeutics公司首席财务官。在加入Apogee之前，Henderson女士于2020年12月至2022年11月担任Adagio Therapeutics, Inc.（现为Invivyd，Inc.）（纳斯达克：IVVD）的首席财务官和首席商务官。Adagio Therapeutics，Inc.是一家为冠状病毒开发抗体疗法的生物技术公司。在加入Adagio Therapeutics之前，亨德森女士于2018年6月至2020年12月担任私营病毒免疫肿瘤公司Turnstone Biologics Corp.的首席财务官,2017年1月至2018年6月担任基因治疗公司Voyager Therapeutics, Inc.（纳斯达克：VYGR）的首席财务官和企业发展高级副总裁，并于2013年2月至2016年11月担任私营肿瘤生物制药公司Kolltan制药公司的高级副总裁、首席财务和业务官，Kolltan制药被Kolltan制药收购之前，在医疗保健投资银行工作了近20年后，亨德森在生物制药公司担任过各种财务和业务发展主管职务。在过去五年中，亨德森女士自2019年4月起担任生物技术公司Akero Therapeutics, Inc.（纳斯达克：AKRO）的董事会成员，自2018年1月起担任生物制药公司IVERIC Bio，Inc.（纳斯达克：ISEE）的董事会成员，以及私营生物制药公司Ventus Therapeutics，Inc.的董事会成员。2018年10月至2021年11月，她还担任生物制药公司Sesen Bio公司（纳斯达克：SESN）的董事会成员。亨德森女士还在南方卫理公会大学戴德曼学院执行委员会任职。亨德森在杜克大学获得了心理学学士学位。
- Jane Pritchett Henderson,has served as Apogee Therapeutics, Inc. Chief Financial Officer since January 2023. Prior to joining Apogee, Ms. Henderson served as the Chief Financial Officer and Chief Business Officer of Adagio Therapeutics, Inc. (now Invivyd, Inc.) (Nasdaq: IVVD), a biotechnology company developing antibody therapeutics for coronaviruses, from December 2020 to November 2022. Prior to joining Adagio Therapeutics, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics Corp., a private viral immuno-oncology company, from June 2018 to December 2020, as Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company, from January 2017 to June 2018, and as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., a private oncology biopharmaceutical company, from February 2013 until November 2016, when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in health care investment banking. During the past five years, Ms. Henderson has served on the board of directors of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since April 2019, IVERIC Bio, Inc. (Nasdaq: ISEE), a biopharmaceutical company, since January 2018, and Ventus Therapeutics, Inc., a private biopharmaceutical company. She also served on the board of directors of Sesen Bio Inc. (Nasdaq: SESN), a biopharmaceutical company, from October 2018 to November 2021. Ms. Henderson also serves on the Dedman College Executive Board of Southern Methodist University. Ms. Henderson received a B.S. in psychology from Duke University.
- Ming Fang
-
明芳自2021年9月起担任董事会成员。方先生是Redmile Group，LLC的董事总经理，该公司是一家专注于医疗保健的投资公司。在2016年加入Redmile之前，方先生曾在医疗保健领域工作，曾担任安科投资的投资者、麦肯锡公司和ZS协会的顾问以及吉利德公司的运营商。他获得了加州大学伯克利分校的学士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位。
Ming Fang has served as a member of board of directors since September 2021. Mr. Fang is a Managing Director at Redmile Group, LLC, a healthcare focused investment firm. Prior to joining Redmile in 2016, Mr. Fang worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead. He received a B.A. from the University of California, Berkeley and an M.B.A. from the Wharton School of Business of the University of Pennsylvania. - 明芳自2021年9月起担任董事会成员。方先生是Redmile Group，LLC的董事总经理，该公司是一家专注于医疗保健的投资公司。在2016年加入Redmile之前，方先生曾在医疗保健领域工作，曾担任安科投资的投资者、麦肯锡公司和ZS协会的顾问以及吉利德公司的运营商。他获得了加州大学伯克利分校的学士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位。
- Ming Fang has served as a member of board of directors since September 2021. Mr. Fang is a Managing Director at Redmile Group, LLC, a healthcare focused investment firm. Prior to joining Redmile in 2016, Mr. Fang worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead. He received a B.A. from the University of California, Berkeley and an M.B.A. from the Wharton School of Business of the University of Pennsylvania.
- William J. Rieflin
-
William J. Rieflin自2011年3月担任董事会成员。自2010年9月他在NGM生物制药股份有限公司担任首席执行官和董事，该公司是一家生物技术公司。从2004年直到2010年他担任XenoPort股份有限公司总裁，XenoPort股份有限公司是一家生物技术公司，并主要致力于运输性前体药物的发现与开发。从1996年到2004年，他在Tularik股份有限公司担任各类职务，该公司是一家生物技术公司并主要致力于基因表达规则备的选药物产品的发现与开发，他在该公司担任的最近的职务有负责企业管理的执行副总裁、首席财务官、法律总顾问以及秘书长。Amgen股份有限公司是一家生物技术公司，该公司于2004年收购Tularik公司。Rieflin先生目前担任XenoPort股份有限公司和NGM生物制药股份有限公司董事。Rieflin先生从康奈尔大学获得学士学位，从芝加哥大学商学院获得工商管理学硕士学位，从斯坦福大学法学院获得法学博士学位。
William J. Rieflin became Executive Chairman of Ngm Biopharmaceuticals, Inc. Board of Directors in September 2018 after having served as Ngm Biopharmaceuticals, Inc. Chief Executive Officer and a member of Ngm Biopharmaceuticals, Inc. Board of Directors since September 2010. From 2004 until 2010 he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004 he held various positions with Tularik, a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression that was acquired by Amgen in 2004 most recently serving as Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Mr. Rieflin has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015 and Kallyope Inc. since 2016. Mr. Rieflin also served as a director of Flexus Biosciences until its acquisition in 2015 a director of XenoPort until its acquisition in 2016 and as a director of Anacor Pharmaceuticals until its acquisition in 2016. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School. - William J. Rieflin自2011年3月担任董事会成员。自2010年9月他在NGM生物制药股份有限公司担任首席执行官和董事，该公司是一家生物技术公司。从2004年直到2010年他担任XenoPort股份有限公司总裁，XenoPort股份有限公司是一家生物技术公司，并主要致力于运输性前体药物的发现与开发。从1996年到2004年，他在Tularik股份有限公司担任各类职务，该公司是一家生物技术公司并主要致力于基因表达规则备的选药物产品的发现与开发，他在该公司担任的最近的职务有负责企业管理的执行副总裁、首席财务官、法律总顾问以及秘书长。Amgen股份有限公司是一家生物技术公司，该公司于2004年收购Tularik公司。Rieflin先生目前担任XenoPort股份有限公司和NGM生物制药股份有限公司董事。Rieflin先生从康奈尔大学获得学士学位，从芝加哥大学商学院获得工商管理学硕士学位，从斯坦福大学法学院获得法学博士学位。
- William J. Rieflin became Executive Chairman of Ngm Biopharmaceuticals, Inc. Board of Directors in September 2018 after having served as Ngm Biopharmaceuticals, Inc. Chief Executive Officer and a member of Ngm Biopharmaceuticals, Inc. Board of Directors since September 2010. From 2004 until 2010 he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004 he held various positions with Tularik, a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression that was acquired by Amgen in 2004 most recently serving as Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Mr. Rieflin has served as a director at RAPT Therapeutics, Inc., a publicly-traded biotechnology company, since 2015 and Kallyope Inc. since 2016. Mr. Rieflin also served as a director of Flexus Biosciences until its acquisition in 2015 a director of XenoPort until its acquisition in 2016 and as a director of Anacor Pharmaceuticals until its acquisition in 2016. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.
- Laurent Fischer
-
Laurent Fischer自2017年7月以来一直担任我们的董事之一。Fischer博士自2016年11月被Tobira Therapeutics收购以来，一直担任Allergan（一家全球制药公司）肝脏治疗领域的高级副总裁，主管，自2013年起担任首席执行官。Fischer博士自2017年3月起担任Frazier梦百合Partners生命科学团队的高级顾问。他此前曾担任Jennerex，Inc.（一流的肝癌溶瘤免疫疗法公司，被Sillajen公司以1.5亿美元收购）的主席兼首席执行官。他曾担任Ocera Therapeutics公司的联席创始人、总裁兼首席执行官，也曾担任DuPont-Merck公司、DuPont Pharmaceuticals公司、Hoffmann-La Roche公司的肝脏疾病、病毒学和肿瘤学高级职务。Fischer博士还担任MirumPharmaceuticals，Inc.的董事。Fischer博士在日内瓦大学（University of Geneva）获得本科学位，在瑞士日内瓦医学院（Geneva Medical School，Switzerland）获得医学学位。
Laurent Fischer,has served as a member of the Board since June 2019. Dr. Fischer has served as the President and Chief Executive Officer of Adverum Biotechnologies, Inc., a clinical stage gene therapy company, since June 2020. Prior to Adverum, he served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc, a pharmaceutical company, from November 2016 to June 2020. Previously, he served as Chief Executive Officer of Tobira Therapeutics, Inc., a public biotechnology company, until its acquisition by Allergan in November 2016. From 2012 to 2014, Dr. Fischer served as Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc. Prior to Jennerex, Dr. Fischer was President and Chief Executive Officer of Ocera Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases, since 2005. Prior to Ocera, Dr. Fischer was President and Chief Executive Officer of life sciences company Auxeris Therapeutics, Inc. from 2003 to 2005, President and Chief Operating Officer of technology company RXCentric.com, Inc. (now part of Allscripts Healthcare Solutions, Inc.) from 1999 to 2000 and Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer served as Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck from 1997 to 1999. From 1995 to 1997, Dr. Fischer served as Medical Director for the Virology Group at healthcare company Hoffman-LaRoche, Ltd. Dr. Fischer currently serves on the boards of directors of public biopharmaceutical companies Adverum and CTI BioPharma Corp., where he serves as Chairman, and privately held biopharmaceutical company Lycia Therapeutics, Inc. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland. - Laurent Fischer自2017年7月以来一直担任我们的董事之一。Fischer博士自2016年11月被Tobira Therapeutics收购以来，一直担任Allergan（一家全球制药公司）肝脏治疗领域的高级副总裁，主管，自2013年起担任首席执行官。Fischer博士自2017年3月起担任Frazier梦百合Partners生命科学团队的高级顾问。他此前曾担任Jennerex，Inc.（一流的肝癌溶瘤免疫疗法公司，被Sillajen公司以1.5亿美元收购）的主席兼首席执行官。他曾担任Ocera Therapeutics公司的联席创始人、总裁兼首席执行官，也曾担任DuPont-Merck公司、DuPont Pharmaceuticals公司、Hoffmann-La Roche公司的肝脏疾病、病毒学和肿瘤学高级职务。Fischer博士还担任MirumPharmaceuticals，Inc.的董事。Fischer博士在日内瓦大学（University of Geneva）获得本科学位，在瑞士日内瓦医学院（Geneva Medical School，Switzerland）获得医学学位。
- Laurent Fischer,has served as a member of the Board since June 2019. Dr. Fischer has served as the President and Chief Executive Officer of Adverum Biotechnologies, Inc., a clinical stage gene therapy company, since June 2020. Prior to Adverum, he served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc, a pharmaceutical company, from November 2016 to June 2020. Previously, he served as Chief Executive Officer of Tobira Therapeutics, Inc., a public biotechnology company, until its acquisition by Allergan in November 2016. From 2012 to 2014, Dr. Fischer served as Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc. Prior to Jennerex, Dr. Fischer was President and Chief Executive Officer of Ocera Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases, since 2005. Prior to Ocera, Dr. Fischer was President and Chief Executive Officer of life sciences company Auxeris Therapeutics, Inc. from 2003 to 2005, President and Chief Operating Officer of technology company RXCentric.com, Inc. (now part of Allscripts Healthcare Solutions, Inc.) from 1999 to 2000 and Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer served as Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck from 1997 to 1999. From 1995 to 1997, Dr. Fischer served as Medical Director for the Virology Group at healthcare company Hoffman-LaRoche, Ltd. Dr. Fischer currently serves on the boards of directors of public biopharmaceutical companies Adverum and CTI BioPharma Corp., where he serves as Chairman, and privately held biopharmaceutical company Lycia Therapeutics, Inc. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland.
高管简历
中英对照 | 中文 | 英文- Aetna Wun Trombley
Aetna Wun Trombley自2020年4月起担任首席执行官兼总裁、董事会成员。Trombley博士自2023年10月起担任风险生物技术公司TCG Labs Soleil的战略董事会成员，此前曾于2016年5月至2024年1月担任临床阶段生物技术公司Carmot Therapeutics Inc.（被F. Hoffmann La Roche Ltd收购）的董事会成员。从2011年9月到2020年3月，Trombley博士在生物技术公司NGM生物制药公司担任越来越重要的职务，最近担任总裁兼首席运营官。Trombley博士此前曾在诺华公司和麦肯锡公司任职。Trombley博士获得了加州大学圣地亚哥分校的化学学士学位和麻省理工学院的化学博士学位。
Aetna Wun Trombley has served as Chief Executive Officer and President and a member of board of directors since April 2020. Dr. Trombley has served as a member of the strategic board of TCG Labs Soleil, a venture biotechnology company, since October 2023 and previously served as a member of the board of directors of Carmot Therapeutics Inc. (acquired by F. Hoffmann La Roche Ltd), a clinical stage biotechnology company, from May 2016 to January 2024. From September 2011 to March 2020, Dr. Trombley held roles of increasing responsibility at NGM Biopharmaceuticals, Inc., a biotechnology company, most recently as President and Chief Operating Officer. Dr. Trombley previously held positions with Novartis AG and McKinsey & Company. Dr. Trombley received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.- Aetna Wun Trombley自2020年4月起担任首席执行官兼总裁、董事会成员。Trombley博士自2023年10月起担任风险生物技术公司TCG Labs Soleil的战略董事会成员，此前曾于2016年5月至2024年1月担任临床阶段生物技术公司Carmot Therapeutics Inc.（被F. Hoffmann La Roche Ltd收购）的董事会成员。从2011年9月到2020年3月，Trombley博士在生物技术公司NGM生物制药公司担任越来越重要的职务，最近担任总裁兼首席运营官。Trombley博士此前曾在诺华公司和麦肯锡公司任职。Trombley博士获得了加州大学圣地亚哥分校的化学学士学位和麻省理工学院的化学博士学位。
- Aetna Wun Trombley has served as Chief Executive Officer and President and a member of board of directors since April 2020. Dr. Trombley has served as a member of the strategic board of TCG Labs Soleil, a venture biotechnology company, since October 2023 and previously served as a member of the board of directors of Carmot Therapeutics Inc. (acquired by F. Hoffmann La Roche Ltd), a clinical stage biotechnology company, from May 2016 to January 2024. From September 2011 to March 2020, Dr. Trombley held roles of increasing responsibility at NGM Biopharmaceuticals, Inc., a biotechnology company, most recently as President and Chief Operating Officer. Dr. Trombley previously held positions with Novartis AG and McKinsey & Company. Dr. Trombley received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
- Chin Lee
Chin Lee ，自2022年3月1日起担任首席医疗官。此前，Lee 博士曾担任副总裁，临床科学负责人，首席医疗官TeavaveBiopHAMA公司，自2021年4月以来。在此之前，从2018年1月到2021年4月，Lee 博士是GeNeNeTeaCompany的GeNeTeaResearch & IndestRealGrand，GeNeTeaCompany Inc.的领先集团医疗总监。此前，Lee 博士在EI Lely&公司从2010年1月起至2018年1月起担任全球高级医学总监的角色。2006年9月至2010年1月，他还担任雅培实验室免疫科学组副医学主任。Lee 博士获得生物学学士学位，北卡罗来纳大学教堂山分校医学博士，西北大学费因伯格医学院医学博士。
Chin Lee has served as Chief Medical Officer since February 2025. Prior to joining Lycia Therapeutics, Inc., Dr. Lee served in various roles at Allakos Inc., a biotechnology company, most recently as Chief Medical Officer from February 2024 to February 2025 and as Executive Vice President from August 2023 to February 2024. From March 2022 to August 2023, Dr. Lee served as Chief Medical Officer at Connect Biopharma Holdings Limited, a clinical stage biopharmaceutical company, and from April 2021 to March 2022, as Chief Medical Officer, Vice President and Head of Clinical Science at Theravance Biopharma US, Inc., a biopharmaceutical company. Dr. Lee previously held positions at Genentech, Inc., Eli Lilly and Company and Abbott Laboratories (now AbbVie Inc.) and served as a faculty member at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received a B.S. in Biology and an M.D. from the University of North Carolina at Chapel Hill and an M.P.H. from Northwestern University.- Chin Lee ，自2022年3月1日起担任首席医疗官。此前，Lee 博士曾担任副总裁，临床科学负责人，首席医疗官TeavaveBiopHAMA公司，自2021年4月以来。在此之前，从2018年1月到2021年4月，Lee 博士是GeNeNeTeaCompany的GeNeTeaResearch & IndestRealGrand，GeNeTeaCompany Inc.的领先集团医疗总监。此前，Lee 博士在EI Lely&公司从2010年1月起至2018年1月起担任全球高级医学总监的角色。2006年9月至2010年1月，他还担任雅培实验室免疫科学组副医学主任。Lee 博士获得生物学学士学位，北卡罗来纳大学教堂山分校医学博士，西北大学费因伯格医学院医学博士。
- Chin Lee has served as Chief Medical Officer since February 2025. Prior to joining Lycia Therapeutics, Inc., Dr. Lee served in various roles at Allakos Inc., a biotechnology company, most recently as Chief Medical Officer from February 2024 to February 2025 and as Executive Vice President from August 2023 to February 2024. From March 2022 to August 2023, Dr. Lee served as Chief Medical Officer at Connect Biopharma Holdings Limited, a clinical stage biopharmaceutical company, and from April 2021 to March 2022, as Chief Medical Officer, Vice President and Head of Clinical Science at Theravance Biopharma US, Inc., a biopharmaceutical company. Dr. Lee previously held positions at Genentech, Inc., Eli Lilly and Company and Abbott Laboratories (now AbbVie Inc.) and served as a faculty member at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received a B.S. in Biology and an M.D. from the University of North Carolina at Chapel Hill and an M.P.H. from Northwestern University.
- Chin Lee
Chin Lee自2025年2月起担任首席医疗官。在加入Lycia Therapeutics，Inc.之前，Lee博士曾在生物技术公司Allakos Inc.担任过各种职务，最近一次是在2024年2月至2025年2月期间担任首席医疗官，并在2023年8月至2024年2月期间担任执行副总裁。2022年3月至2023年8月，Lee博士在临床阶段生物制药公司康乃德生物制药控股有限公司担任首席医疗官，并于2021年4月至2022年3月在生物制药公司Theravance Biopharma美国公司担任首席医疗官、副总裁兼临床科学主管。Lee博士此前曾在基因泰克、礼来和公司以及雅培（现为艾伯维公司）任职，并曾在西北大学范伯格医学院风湿病学系担任教员。Lee博士获得了北卡罗来纳大学教堂山分校的生物学学士学位和医学博士学位，以及西北大学的医学硕士学位。
Chin Lee has served as Chief Medical Officer since February 2025. Prior to joining Lycia Therapeutics, Inc., Dr. Lee served in various roles at Allakos Inc., a biotechnology company, most recently as Chief Medical Officer from February 2024 to February 2025 and as Executive Vice President from August 2023 to February 2024. From March 2022 to August 2023, Dr. Lee served as Chief Medical Officer at Connect Biopharma Holdings Limited, a clinical stage biopharmaceutical company, and from April 2021 to March 2022, as Chief Medical Officer, Vice President and Head of Clinical Science at Theravance Biopharma US, Inc., a biopharmaceutical company. Dr. Lee previously held positions at Genentech, Inc., Eli Lilly and Company and Abbott Laboratories (now AbbVie Inc.) and served as a faculty member at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received a B.S. in Biology and an M.D. from the University of North Carolina at Chapel Hill and an M.P.H. from Northwestern University.- Chin Lee自2025年2月起担任首席医疗官。在加入Lycia Therapeutics，Inc.之前，Lee博士曾在生物技术公司Allakos Inc.担任过各种职务，最近一次是在2024年2月至2025年2月期间担任首席医疗官，并在2023年8月至2024年2月期间担任执行副总裁。2022年3月至2023年8月，Lee博士在临床阶段生物制药公司康乃德生物制药控股有限公司担任首席医疗官，并于2021年4月至2022年3月在生物制药公司Theravance Biopharma美国公司担任首席医疗官、副总裁兼临床科学主管。Lee博士此前曾在基因泰克、礼来和公司以及雅培（现为艾伯维公司）任职，并曾在西北大学范伯格医学院风湿病学系担任教员。Lee博士获得了北卡罗来纳大学教堂山分校的生物学学士学位和医学博士学位，以及西北大学的医学硕士学位。
- Chin Lee has served as Chief Medical Officer since February 2025. Prior to joining Lycia Therapeutics, Inc., Dr. Lee served in various roles at Allakos Inc., a biotechnology company, most recently as Chief Medical Officer from February 2024 to February 2025 and as Executive Vice President from August 2023 to February 2024. From March 2022 to August 2023, Dr. Lee served as Chief Medical Officer at Connect Biopharma Holdings Limited, a clinical stage biopharmaceutical company, and from April 2021 to March 2022, as Chief Medical Officer, Vice President and Head of Clinical Science at Theravance Biopharma US, Inc., a biopharmaceutical company. Dr. Lee previously held positions at Genentech, Inc., Eli Lilly and Company and Abbott Laboratories (now AbbVie Inc.) and served as a faculty member at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received a B.S. in Biology and an M.D. from the University of North Carolina at Chapel Hill and an M.P.H. from Northwestern University.
- Sofia Touami
Sofia Touami自2023年7月起担任首席商务官。在加入Lycia Therapeutics，Inc.之前，Touami博士于2021年5月至2023年7月期间担任生物技术公司Hexagon Bio的首席商务官。此前，她于2019年12月至2021年5月在生物技术公司Frontier Medicines担任业务发展副总裁，于2010年1月至2019年11月在生物技术公司NGM生物制药公司担任业务发展和联盟管理高级总监。在此之前，Touami博士曾在Cerimon Pharmaceuticals，Inc.、Oscient Pharmaceuticals Corporation和Genesoft Pharmaceuticals，Inc.任职。Touami博士在圣路易斯华盛顿大学获得化学学士学位，在斯坦福大学获得有机化学博士学位，并在斯克里普斯研究所完成博士后研究。
Sofia Touami has served as Chief Business Officer since July 2023. Prior to joining Lycia Therapeutics, Inc., Dr. Touami served as Chief Business Officer at Hexagon Bio, a biotechnology company, from May 2021 until July 2023. Previously, she served as Vice President of Business Development at Frontier Medicines, a biotechnology company, from December 2019 to May 2021, as Senior Director of Business Development and Alliance Management at NGM Biopharmaceuticals, Inc., a biotechnology company, from January 2010 to November 2019. Prior to that, Dr. Touami held positions with Cerimon Pharmaceuticals, Inc., Oscient Pharmaceuticals Corporation and Genesoft Pharmaceuticals, Inc. Dr. Touami received an A.B. in Chemistry from Washington University in St. Louis, a Ph.D. in Organic Chemistry from Stanford University, and completed postdoctoral studies at The Scripps Research Institute.- Sofia Touami自2023年7月起担任首席商务官。在加入Lycia Therapeutics，Inc.之前，Touami博士于2021年5月至2023年7月期间担任生物技术公司Hexagon Bio的首席商务官。此前，她于2019年12月至2021年5月在生物技术公司Frontier Medicines担任业务发展副总裁，于2010年1月至2019年11月在生物技术公司NGM生物制药公司担任业务发展和联盟管理高级总监。在此之前，Touami博士曾在Cerimon Pharmaceuticals，Inc.、Oscient Pharmaceuticals Corporation和Genesoft Pharmaceuticals，Inc.任职。Touami博士在圣路易斯华盛顿大学获得化学学士学位，在斯坦福大学获得有机化学博士学位，并在斯克里普斯研究所完成博士后研究。
- Sofia Touami has served as Chief Business Officer since July 2023. Prior to joining Lycia Therapeutics, Inc., Dr. Touami served as Chief Business Officer at Hexagon Bio, a biotechnology company, from May 2021 until July 2023. Previously, she served as Vice President of Business Development at Frontier Medicines, a biotechnology company, from December 2019 to May 2021, as Senior Director of Business Development and Alliance Management at NGM Biopharmaceuticals, Inc., a biotechnology company, from January 2010 to November 2019. Prior to that, Dr. Touami held positions with Cerimon Pharmaceuticals, Inc., Oscient Pharmaceuticals Corporation and Genesoft Pharmaceuticals, Inc. Dr. Touami received an A.B. in Chemistry from Washington University in St. Louis, a Ph.D. in Organic Chemistry from Stanford University, and completed postdoctoral studies at The Scripps Research Institute.
- Amy Bachrodt
Amy Bachrodt自2026年6月起担任首席财务官。在加入Lycia Therapeutics，Inc.之前，Bachrodt女士曾于2020年5月至2026年5月在生物技术公司Maze Therapeutics，Inc.担任多个职务，最近担任财务高级副总裁。此前，Bachrodt女士于2018年4月至2020年5月在临床阶段生物技术公司Myovant Sciences Ltd.担任高级董事兼FP & A负责人。从2008年9月到2018年4月，Bachrodt女士在生物技术公司基因泰克担任越来越重要的职务。Bachrodt女士获得丹尼森大学经济学学士学位和圣母大学会计学硕士学位。
Amy Bachrodt has served as Chief Financial Officer since June 2026. Prior to joining Lycia Therapeutics, Inc., Ms. Bachrodt served in various roles at Maze Therapeutics, Inc., a biotechnology company, from May 2020 to May 2026, most recently as Senior Vice President of Finance. Previously, Ms. Bachrodt served as Senior Director and Head of FP&A at Myovant Sciences Ltd., a clinical stage biotechnology company, from April 2018 to May 2020. From September 2008 to April 2018, Ms. Bachrodt held roles of increasing responsibility at Genentech, Inc., a biotechnology company. Ms. Bachrodt received a B.A. in Economics from Denison University and an M.S.A. in Accounting from the University of Notre Dame.- Amy Bachrodt自2026年6月起担任首席财务官。在加入Lycia Therapeutics，Inc.之前，Bachrodt女士曾于2020年5月至2026年5月在生物技术公司Maze Therapeutics，Inc.担任多个职务，最近担任财务高级副总裁。此前，Bachrodt女士于2018年4月至2020年5月在临床阶段生物技术公司Myovant Sciences Ltd.担任高级董事兼FP & A负责人。从2008年9月到2018年4月，Bachrodt女士在生物技术公司基因泰克担任越来越重要的职务。Bachrodt女士获得丹尼森大学经济学学士学位和圣母大学会计学硕士学位。
- Amy Bachrodt has served as Chief Financial Officer since June 2026. Prior to joining Lycia Therapeutics, Inc., Ms. Bachrodt served in various roles at Maze Therapeutics, Inc., a biotechnology company, from May 2020 to May 2026, most recently as Senior Vice President of Finance. Previously, Ms. Bachrodt served as Senior Director and Head of FP&A at Myovant Sciences Ltd., a clinical stage biotechnology company, from April 2018 to May 2020. From September 2008 to April 2018, Ms. Bachrodt held roles of increasing responsibility at Genentech, Inc., a biotechnology company. Ms. Bachrodt received a B.A. in Economics from Denison University and an M.S.A. in Accounting from the University of Notre Dame.
- Steve Staben
Steve Staben自2021年10月起担任首席科学官。在加入Lycia Therapeutics，Inc.之前，Staben博士曾在生物技术公司基因泰克担任多个领导职务，最近一次是在2007年6月至2021年10月担任药物化学和新模式化学高级/执行董事。Staben博士在西华盛顿大学获得化学学士学位，在加州大学伯克利分校获得有机化学博士学位。
Steve Staben has served as Chief Scientific Officer since October 2021. Prior to joining Lycia Therapeutics, Inc., Dr. Staben held various leadership positions at Genentech, Inc., a biotechnology company, most recently as Senior/Executive Director of Medicinal Chemistry and New Modalities Chemistry, from June 2007 to October 2021. Dr. Staben received a B.S. in Chemistry from Western Washington University and a Ph.D. in Organic Chemistry from the University of California, Berkeley.- Steve Staben自2021年10月起担任首席科学官。在加入Lycia Therapeutics，Inc.之前，Staben博士曾在生物技术公司基因泰克担任多个领导职务，最近一次是在2007年6月至2021年10月担任药物化学和新模式化学高级/执行董事。Staben博士在西华盛顿大学获得化学学士学位，在加州大学伯克利分校获得有机化学博士学位。
- Steve Staben has served as Chief Scientific Officer since October 2021. Prior to joining Lycia Therapeutics, Inc., Dr. Staben held various leadership positions at Genentech, Inc., a biotechnology company, most recently as Senior/Executive Director of Medicinal Chemistry and New Modalities Chemistry, from June 2007 to October 2021. Dr. Staben received a B.S. in Chemistry from Western Washington University and a Ph.D. in Organic Chemistry from the University of California, Berkeley.